(Q37738355)

22 August 2017

1 reference

title

Lp-PLA2: A new target for statin therapy (English)

1 reference

22 August 2017

1 reference

Lynne T Braun

1

1 reference

22 August 2017

Michael H Davidson

series ordinal

2

1 reference

22 August 2017

publication date

1 January 2010

1 reference

Current Atherosclerosis Reports

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

29-33

1 reference

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0074-Y

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and risk of stroke

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia

1 reference

12 December 2020

Clinical significance of statin pleiotropic effects: hypotheses versus evidence

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention

1 reference

12 December 2020

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2

1 reference

12 December 2020

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

12 December 2020

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

1 reference

12 December 2020

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

1 reference

12 December 2020

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

1 reference

12 December 2020

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

1 reference

12 December 2020

10.1007/S11883-009-0074-Y

Identifiers

DOI

1 reference

22 August 2017

1 reference